Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
With
Jordana B. Cohen, MD, MSCE
Hanff, Thomas C., M.D., MPH
University of Arizona
Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud
Hospital Nacional Edgardo Rebagliati Martins
Hospital Español de Mendoza
Stanford University
Ottawa Hospital Research Institute
Hospital Civil de Guadalajara
Universidad Catolica Argentina
Caja Nacional de Salud
Departamento de Medicina, Hospital Alberto Barton Thompson, Callao, Peru
Karolinska Institutet
University of Miami
Division of Cardiology, Department of Medicine, Hospital Español, Buenos Aires, Argentina
University of Michigan
Jesse Chittams, MS
Duke University
Vasquez, Charles R., M.D.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age 18 years or older
2. Hospitalization with a suspected diagnosis of COVID-19, based on: (a) A compatible clinical presentation with a positive laboratory test for SARS-CoV-2, or (b) Considered by the primary team to be a Person Under Investigation due to undergo testing for COVID-19 in addition to compatible pulmonary infiltrates on chest x-ray (mutilobar, intersticial or ground glass opacities).
3. Use of ACEI or ARB as an outpatient prior to hospital admission.
You may not be if
1. Systolic blood pressure \<100 mmHg.
2. Systolic blood pressure \> 180 mmHg or \>160 if unable to substitute ACEIs/ARBs for another antihypertensive class, per the investigator's discretion.
3. Diastolic blood pressure \> 110 mmHg
4. Known history of heart failure with reduced ejection fraction (EF \<40%) on their most recent echo and/or clinical heart failure with unknown EF (i.e. no echo in approximately the past year).
5. Serum K\>5.0 mEq/L on admission.
6. Known pregnancy or breastfeeding.
7. eGFR \<30 mL/min/1.73m2
8. \>50% increase in creatinine (to a creatinine \>1.5 mg/dl) compared to most recent creatinine in the past six months, if available
9. Urine protein-to-creatitine ratio \> 3 g/g or proteinuria \> 3 g/24-hours within the past year
10. Ongoing treatment with aliskiren or sacubitril-valsartan.
11. Inability to obtain informed consent from patient.
12. Inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.
Clareo Health | Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019
